Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 190-199

  Hegde, Sharath S ^a   Hughes, Adam D ^a   Chen, Yan ^a   Steinfeld, Tod ^a   Jasper, Jeffrey R ^a   Lee, Tae Weon ^a   McNamara, Alexander ^a   Martin, William J ^a   Pulido Rios, M Teresa ^a   Mammen, Mathai ^a  

^a THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATEFENTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; FORMOTEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; MUSCARINIC RECEPTOR BLOCKING AGENT; RADIOLIGAND; RECEPTOR SUBTYPE; RECOMBINANT RECEPTOR; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BRONCHODILATING AGENT; CARBAMIC ACID DERIVATIVE; GSK961081; MUSCARINIC RECEPTOR; PROTEIN BINDING; QUINOLONE DERIVATIVE; SCOPOLAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRONCHOCONSTRICTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EC50; GUINEA PIG; HEART STROKE VOLUME; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NEBULIZER; NONHUMAN; RECEPTOR AFFINITY; RESPIRATORY TRACT DISEASE; SMOOTH MUSCLE RELAXATION; TRACHEA; VENTILATOR; ANALOGS AND DERIVATIVES; ANIMAL; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; DRUG SCREENING; HAMSTER; HEK293 CELL LINE; LUNG; METABOLISM; MUSCLE RELAXATION; PHYSIOLOGY; SMOOTH MUSCLE; TISSUE DISTRIBUTION;

ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ALBUTEROL; ANIMALS; BRONCHODILATOR AGENTS; CARBAMATES; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HEK293 CELLS; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; MUSCLE RELAXATION; MUSCLE, SMOOTH; PROTEIN BINDING; QUINOLONES; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, MUSCARINIC; SCOPOLAMINE DERIVATIVES; TISSUE DISTRIBUTION; TRACHEA;

EID: 84907168931     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.216861     Document Type: Article

References (25)

1. Aisaka K, Gross SS, Griffith OW, and Levi R (1989) L-arginine availability determines the duration of acetylcholine-induced systemic vasodilation in vivo. Biochem Biophys Res Commun 163:710-717.
2. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br Pharmacol Chemother 14:48-58.
3. Barnes PJ (1993) Muscarinic receptor subtypes in airways. Life Sci 52:521-527.
4. Barnes PJ (1998) Pharmacology of airway smooth muscle. Am J Respir Crit Care Med 158:S123-S132.
5. Barnes PJ, Belvisi MG, Mak JC, Haddad EB, and O'Connor B (1995) Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 56:853-859.
6. Bateman ED, Kornmann O, Ambery C, and Norris V (2013) Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 26:581-587.
7. Cazzola M and Matera MG (2008) Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 155:291-299.
8. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Coleman RA (2009) On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol 158:180-182.
10. Decramer M, Janssens W, and Miravitlles M (2012) Chronic obstructive pulmonary disease. Lancet 379:1341-1351.
11. Gaebel K, McIvor RA, Xie F, Blackhouse G, Robertson D, Assasi N, Hernandez P, and Goeree R (2011) Triple therapy for the management of COPD: a review. COPD 8:206-243.
12. Howell RE, Laemont KD, Kovalsky MP, Lowe VC, Waid PP, Kinnier WJ, and Noronha-Blob L (1994) Pulmonary pharmacology of a novel, smooth muscleselective muscarinic antagonist in vivo. J Pharmacol Exp Ther 270:546-553.
13. Hughes AD, McNamara A, and Steinfeld T (2012) Multivalent dual pharmacology muscarinic antagonist and β2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 51:71-95.
14. Jacobsen JR, Aiyar J, Hegde S, Hughes AD, and Mammen M (2010). Dual pharmacology bronchodilators for the treatment of COPD, in New Drugs and Targets for Asthma and COPD (Hansel TT and Barnes PJ eds) pp 39-45, Karger, Basel.
15. January B, Seibold A, Allal C, Whaley BS, Knoll BJ, Moore RH, Dickey BF, Barber R, and Clark RB (1998) Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor. Br J Pharmacol 123:701-711.
16. Kobayashi N, Hasegawa M, Yokoyama K, and Tamura T (1994) Sympathetic betaagonists and cochlear blood flow in guinea pigs. J Otolaryngol 23:97-101.
17. Matthiesen S, Bahulayan A, Kempkens S, Haag S, Fuhrmann M, Stichnote C, Juergens UR, and Racké K (2006) Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am J Respir Cell Mol Biol 35:621-627.
18. McNamara A, Pulido-Rios MT, Hegde SS, and Martin WJ (2011) Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents. J Pharmacol Toxicol Methods 63:89-95.
19. McNamara A, Steinfeld T, Pulido-Rios MT, Stangeland E, Hegde SS, Mammen M, and Martin WJ (2012) Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and b(2)-adrenoceptor agonist (MABA). Pulm Pharmacol Ther 25:357-363.
20. Oenema TA, Mensink G, Smedinga L, Halayko AJ, Zaagsma J, Meurs H, Gosens R, and Dekkers BG (2013) Cross-talk between transforming growth factor-β1 and muscarinic M2 receptors augments airway smooth muscle proliferation. Am J Respir Cell Mol Biol 49:18-27.
21. Pera T and Penn RB (2014) Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway. Curr Opin Pharmacol 16:72-81.
22. Proskocil BJ and Fryer AD (2005) Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2:305-310, discussion 311-312.
23. Steinfeld T, Hughes AD, Klein U, Smith JA, and Mammen M (2011) THRX-198321 is a bifunctional muscarinic receptor antagonist and b2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 79: 389-399.
24. Tashkin DP and Ferguson GT (2013) Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 14:49.
25. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, and Nishimura M, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347-365.